Myeloproliferative Neoplasm MPN Clinical Trials Portfolio Recruiting MPN

Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio Recruiting MPN Trials PHAZAR A Phase 1 b Study to assess the safety and tolerability of oral Ruxolitinib in combination (Interventional) with Azacitidine in patients with Advanced Phase MPN, including MDS or AML arising from Accelerated or blast MPN phase MPN Eligibility Criteria: PI: Prof Claire Harrison -Age 16 and over, Diagnosis of ET, PV or MF with either bone marrow blasts (with or without dysplastic changes) or >20% bone marrow blasts, ECOG performance status: 0 -3. CAMBRIDGE The Causes of Clonal Blood Cell Disorders (Observational) Eligibility Criteria: PI: Prof Claire Harrison -Patients with clonal haematological disorders. MEASURES The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (Observational) (MEASURES) Trial: Serial Assessment of Symptomatic Response to Non Experimental All MPN Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms Eligibility Criteria: PI: Dr Deepti Radia -All MPN patients starting a new, therapeutic intervention. TAMARIN (Interventional) All MPN Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloprolife. Rat. Ive Neoplasms Eligibility Criteria: -PV, ET, MF stable disease on hydroxurea, bilirubin or ruxolutinib. No prior thrombosis. Age PI: Prof Claire Harrison over 60, men aged between 50 -59 may be considered, women must be post-menopausal. A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (adv. SM) and BLU-285 -2101 (Interventional) Relapsed or Refractory Myeloid Malignancies Eligibility Criteria: Systemic mastocytosis -Age 18 over and have an ECOG performance status of 0 -3. PI: Dr Deepti Radia Part 1 of study: Patients with adv. SM or other relapsed or refractory myeloid malignancy. Part 2 of study: Patients are split into 3 groups-ASM, AHNMD and MCL MPN Clot (Observational) PVor ET PI Prof C Harrison Treatment of Polycythaemia Vera and Essential Thrombocythaemia: influence on the clot structure. Eligibility Criteria: -All men and women, older than 18 years, with a diagnosis of PV or ET (primary or secondary. PAC 203 (Interventional) Myelofibrosis PI Prof C Harrison ACE-536 (Interventional) Myelofibrosis PI Prof C Harrison An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib Eligibility Criteria: -Diagnosed with PMF, prior ruxolitinib treatment failure, palpable splenomegaly of more than or equal to 5 cm, peripheral blast count of less than 10%. A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence Eligibility Criteria: -Age 18 or over, subject has MPN-associated myelofibrosis, subject has anemia and an ECOG performance score ≤ 2. Includes patients currently on ruxolitinib, but may also not be on the drug DCC-2618 -01 -001 Invictus (Interventional) Systemic Mastocytosis PI: Dr Deepti Radia A multicentre Phase 1, Open-Label Study of DCC-2618 to assess safety, tolerability, efficacy and pharmacokinetics in patients with advanced malignancies. Eligibility criteria: - Age 18 or over, gastrointestinal stromal tumor patients must have KIT it PDGFRA mutation and must have progressed on or had intolerability to at least 1 but not more than 4 lines of systemic anticancer therapy, Systemic mastocytosis (SM patients) must have a confirmed diagnosis of advanced SM according to 2016 world health organisation (WHO) criteria for SM. Realism UK (Observational) Myelofibrosis PI Prof C Harrison An observational study to collate retrospective real world evidence to review the current treatment pathways for Myelofibrosis from across the UK. Eligibility Criteria: - Age 18 and over, diagnosis of MF in the last 5 years, patient has consented to the study and has had at least 1 follow up visit following diagnosis of MF. MPN Trials in Set-up INCYTE INCB 54828 -203 (Interventional) Myeloid lymphoid disorders with 8 p 11 PI Prof C Harrison Navitoclax (ABT 263) (Interventional) Myelofibrosis PI Prof C Harrison A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB 054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR 1 Rearrangement Eligibility Criteria: Age 18 and over, lymphoid or myeloid neoplasm with 8 p 11 rearrangement known to lead to FGFR 1 activation and subjects who are not candidates for stem cell transplantation but have progressed, will be eligible. A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis. Eligibility Criteria: -Age 18 and over, diagnosis of primary MF, PPV_MF or PET_MF, ineligible or unwilling to undergo stem cell transplantation, Subjects must have received ruxolitinib therapy for at least 24 weeks and be on a stable dose of more than 10 mg BID of ruxolitinib more than 8 weeks prior to 1 st dose of navitoclax, ECOG of 0. 1 or 2. INFor. Me. D (Observational) PI Prof C Harrison An observational and biological research study to investigate the genetic and cellular basis of sporadic and familial myeloid disorders. Eligibility Criteria: - Age 2 or over, patients under investigation for or diagnosed with a myeloid or related disorder, patient willing to give consent to the study. Haematology Research contact details Professor Claire Harrison Dr Deepti Radia Email: claire. harrison@gstt. nhs. uk/ Tel: 0207 1882742 Email: deepti. radia@gstt. nhs. uk/ Tel: 0207 -1883423 Dr Donal Mclornan Email: donal. mclornan@nhs. net General Enquiries Haematology. Research. Team@gstt. nhs. uk